Stem Cells Therapy in The Treatment of T1DM
Stem cells open up a wide spectrum of diabetes research possibilities. Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with T1DM to withdraw from insulin therapy. Furthermore, autologous transplantation using induced pluripotent stem cells-derived islet cells is expected to have the potential to treat T1DM patients without requiring immunosuppressive therapy.
Services
Stem Cell Reprogramming
Sendai virus (RNA virus) based reprogramming can be used to reprogram a wide range of cell types and origins. The reprogramming process is based on transfection of transcriptional factor genes (Oct4, Sox2, c-Myc and Klf4).
Stem Cell Culture
We offer a serum-free medium for induced pluripotent stem cells that maintain pluripotency, trilineage differentiation potential and karyotypic stability.
Stem Cell Engineering
Using lipid-base transfection, electroporation, viral approaches or genome engineering tools such as CRISPR or TALEN.
Stem Cell Differentiation
Using consecutive cytokines or signaling modulators to control the differentiation of iPSCs into pancreatic β-cells. Identifying the proliferative signals as well as instructive signals that induce the differentiation process.
Stem Cell Characterization
Includes assessing pluripotency, genomic stability, and safety. And the safety assays include sterility, mycoplasma, endotoxin, and adventitious viral testing.
Top comments (0)